| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Zenas BioPharma, Inc.
13D/A
ZBIO · 98937L105
|
4.9% |
8/19/2026
Event 8/19/2026
|
||||
| Enavate Sciences GP, LLC | 4.9% | |||||
| Zebra Aggregator, LP | 4.9% | |||||
|
CAMP4 Therapeutics Corporation
13D/A
CAMP · 13463J101
|
4.8% |
3/11/2026
Event 3/9/2026
|
||||
| Enavate Sciences GP, LLC | 4.8% | |||||
| Everest Aggregator, LP | 4.8% | |||||
|
Immunome, Inc.
13D/A
IMNM · 45257U108
|
4.3% |
12/22/2025
Event 12/18/2025
|
||||
| Enavate Sciences GP, LLC | 4.3% | |||||
| Immunome Aggregator, LP | 4.3% | |||||
|
Sionna Therapeutics, Inc.
13D
SION · 829401108
|
5.6% |
2/18/2025
Event 2/10/2025
|
||||
| Enavate Sciences GP, LLC | 5.6% | |||||
| Sionna Aggregator, LP | 5.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.